{
  "ticker": "PER",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971723",
  "id": "02971723",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250723",
  "time": "0846",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1ndzwshmjyk.pdf",
  "summary": "- **New preclinical data** shows HMBD-002 combined with radiotherapy improves survival in SCCHN mouse models (35.5 days vs. 27 days, p < 0.05).  \n- **Radiotherapy increases VISTA expression**, a resistance mechanism; HMBD-002 inhibition shifts immune response to pro-inflammatory state.  \n- **Potential clinical application** in SCCHN, breast cancer, lung cancer, or melanoma, though further evaluation is needed.  \n\n**No material trading or capital markets information identified.**",
  "usage": {
    "prompt_tokens": 1540,
    "completion_tokens": 107,
    "total_tokens": 1647,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T23:13:21.353338"
}